Validating commercial antibodies in the most cost-effective way - Jan Voskuil

For more information about 1st International Antibody Validation Meeting 2014, please visit www.stjohnslab...
Antibody Validation Project (Free Trial Size Antibodies) www.stjohnslab...
Western Blotting (WB) - Video Protocol: • Western Blotting (WB) ...
ImmunoHistoChemistry (IHC) - Video Protocol: • ImmunoHistoChemistry (...
Immunocytochemistry (ICC) - Video Protocol: • Immunocytochemistry (I...
Dr Jan Voskuil is Chief Scientific Officer at antibody manufacturer Everest Biotech in Oxfordshire, UK. After specializing in prokaryotic cell biology through his PhD program in Amsterdam, Netherlands, and a postdoc position at Stanford, California, he switched to the science of neurodegenerative diseases at Oxford, UK through postdoc positions at Dunn School of Pathology and at MRC and through a leading position at the Alzheimer drug discovery company Synaptica. He subsequently gained experience in a GLP-regulatory environment in CRO companies both in Oxfordshire and Cambridgeshire, validating assays in
Flow Cytometry and ELISA platforms and writing SOPs. His extensive experience with generating and characterizing monoclonal and polyclonal antibodies in combination with accrued knowledge on immunoassays in academic and commercial environments made him the ideal candidate to take charge in putting Everest Biotech on the global map by ever raising the quality and size of its catalogue and by delivery of adequate technical support. As a result, Everest antibodies are currently part of most globally well-known catalogues, and its products are increasingly recognized as useful alternatives to unfit monoclonal antibodies.

[@Stjohnslabsuk]

Dr Jan Voskuil is Chief Scientific Officer at antibody manufacturer Everest Biotech in Oxfordshire, UK. After specializing in prokaryotic cell biology through his PhD program in Amsterdam, Netherlands, and a postdoc position at Stanford, California, he switched to the science of neurodegenerative diseases at Oxford, UK through postdoc positions at Dunn School of Pathology and at MRC and through a leading position at the Alzheimer drug discovery company Synaptica. He subsequently gained experience in a GLP-regulatory environment in CRO companies both in Oxfordshire and Cambridgeshire, validating assays in Flow Cytometry and ELISA platforms and writing SOPs. His extensive experience with generating and characterizing monoclonal and polyclonal antibodies in combination with accrued knowledge on immunoassays in academic and commercial environments made him the ideal candidate to take charge in putting Everest Biotech on the global map by ever raising the quality and size of its catalogue and by delivery of adequate technical support. As a result, Everest antibodies are currently part of most globally well-known catalogues, and its products are increasingly recognized as useful alternatives to unfit monoclonal antibodies.